Photonic hyperthermia of malignant peripheral nerve sheath tumors at the third near-infrared biowindow
Abstract
Malignant peripheral nerve sheath tumors (MPNSTs), as typical aggressive sarcomas, typically carry a dismal prognosis. Given the insensitivity of these tumors to traditional chemotherapy and the absence of effective targeted drugs, new therapeutic strategies for efficient MPNSTs treatment are urgently needed. Recently, photothermal therapy (PTT) has demonstrated significant potential in cancer theranostics due to its minimally invasive nature and excellent therapeutic outcomes. However, the passive utilization of photothermal agents (PTAs) with poor target specificity and biocompatibility substantially hinders the clinical translation and application of this method. A unique near-infrared laser at the third biowindow (NIR-III) was utilized for photonic hyperthermia treatment of MPNSTs without PTAs. The superficial locations and relatively high collagen content of MPNSTs ensure the efficiency of photothermal tumor ablation and make the NIR-III laser a suitable therapeutic option that has potential for use in clinical applications. Using human MPNST cell line and xenograft models, it can be found that although the NIR-III photothermal treatment efficiency varied among individuals, which was possibly influenced by different endoplasmic reticulum stress responses (ERSRs), the expected antineoplastic effect was ultimately achieved after adjustment of the power density and radiation duration. The present study provides an intriguing noninvasive therapy for MPNSTs that accelerates the clinical translation of PTT while avoiding the biocompatibility issues arising from PTAs.
Data availability
The generic database-'Dryad' has been chosen.The unique identifier: doi:10.5061/dryad.3bk3j9km7All data generated or analysed during this study are included in the manuscript and supporting file.
-
Photonic hyperthermia of malignant peripheral nerve sheath tumors at the third near-infrared biowindowDryad Digital Repository, doi:10.5061/dryad.3bk3j9km7.
Article and author information
Author details
Funding
National Natural Science Foundation of China (82102344)
- Zhichao Wang
National Natural Science Foundation of China (82172228)
- Qingfeng Li
Shanghai Rising star Program (20QA1405600)
- Zhichao Wang
Natural Science Foundation of Shanghai (22ZR1422300)
- Zhichao Wang
Science and Technology Commission of Shanghai Municipality (19JC1413)
- Qingfeng Li
Shanghai Education Development Foundation (19CG18)
- Zhichao Wang
Shanghai Municipal Key Clinical Specialty (shslczdzk00901)
- Qingfeng Li
Innovative research team of high-level local universities in Shanghai (SSMU-ZDCX20180700)
- Qingfeng Li
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animals received humane care in compliance with the guidelines outlined in the Guide for the Care and Use of Laboratory Animals. All procedures were performed in accordance with the guidelines approved by the Shanghai Medical Experimental Animal Care Commission (IACUC: 2019-0008).
Human subjects: The use of photos and magnetic resonance images of MPNST patients was approved by the Ethics Committee of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine (Reference number: SH9H-2019-T163-2). Informed consent and consent to publish were obtained from patients under institutional review board protocols.
Copyright
© 2022, Gu et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.
-
- Cancer Biology
- Cell Biology
Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.